| abstract |
The present disclosure provides methods for treating multiple myeloma using a combination of autologous expanded and activated NK cells from the patient and an antibody that targets an antigen on myeloma cells and/or an antibody that targets the KIR antigen on NK cells, wherein the antibodies elecit ADCC toward myeloma cells. The present disclosure provides methods for treating multiple myeloma using a combination of autologous NK cells and the anti-CS1 antibody elotuzumab. |